Related references
Note: Only part of the references are listed.Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
Sharon E. Frey et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses
Anu Haveri et al.
VACCINE (2019)
Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-Glade antibody responses than homologous prime-boost
Min Z. Levine et al.
NPJ VACCINES (2019)
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
Surender Khurana et al.
NPJ VACCINES (2018)
Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults
Joon Young Song et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans
Min Z. Levine et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination
Daniel F. Hoft et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets
Sudhir Kumar et al.
MOLECULAR BIOLOGY AND EVOLUTION (2016)
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine
Innocent N. Mbawuike et al.
VACCINE (2016)
Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam
Trong Lan Phan et al.
VACCINE (2016)
Highly pathogenic avian influenza viruses H5N2, H5N3, and H5N8 in Taiwan in 2015
Ming-Shiuh Lee et al.
VETERINARY MICROBIOLOGY (2016)
H5N1 influenza virulence, pathogenicity and transmissibility: what do we know?
Gabriele Neumann
FUTURE VIROLOGY (2015)
Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014
Gavin J. D. Smith et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2015)
Symptoms seem to be mild in children infected with avian influenza A (H5N6) and other subtypes
Tianmu Chen et al.
JOURNAL OF INFECTION (2015)
Newly Emergent Highly Pathogenic H5N9 Subtype Avian Influenza A Virus
Yang Yu et al.
JOURNAL OF VIROLOGY (2015)
Human Infection with a Novel Avian Influenza A(H5N6) Virus
Zi-Feng Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial
Joanne M. Langley et al.
VACCINE (2015)
Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children
Chris P. Verschoor et al.
PLOS ONE (2015)
Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets
Rebecca J. Cox et al.
PLOS ONE (2015)
Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore
Jung Pu Hsu et al.
BMC INFECTIOUS DISEASES (2014)
Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant A Randomized Clinical Trial
Robert B. Belshe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population
Maikel V. W. van der Velden et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children < 3 Years of Age
Terry Nolan et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Whole-Genome Sequence of a Reassortant H5N6 Avian Influenza Virus Isolated from a Live Poultry Market in China, 2013
Xian Qi et al.
GENOME ANNOUNCEMENTS (2014)
An Inactivated, Adjuvanted Whole Virion Clade 2.2 H5N1 (A/Chicken/Astana/6/05) Influenza Vaccine Is Safe and Immunogenic in a Single Dose in Humans
Abylay R. Sansyzbay et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
Paul Gillard et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China
Kunkun Zhao et al.
VETERINARY MICROBIOLOGY (2013)
Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects
Ivan Bihari et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine
Li-Wei Cheng et al.
JOURNAL OF VIROLOGICAL METHODS (2012)
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming
Maikel V. W. van der Velden et al.
VACCINE (2012)
Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Timo Vesikari et al.
VACCINE (2012)
Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults
Jessica A. Chichester et al.
VIRUSES-BASEL (2012)
Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
Stephane Heijmans et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Immunogenicity and safety of an AS03A-adjuvanted H5N1 influenza vaccine in a Taiwanese population
Shinn-Jang Hwang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2011)
Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus
S. Grund et al.
JOURNAL OF VIROLOGICAL METHODS (2011)
Safety and Cross-Reactive Immunogenicity of Candidate AS03-Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Kinetics of Neutralizing Antibodies in Patients Naturally Infected by H5N1 Virus
Philippe Buchy et al.
PLOS ONE (2010)
Genetic Diversity of the 2009 Pandemic Influenza A(H1N1) Viruses in Finland
Niina Ikonen et al.
PLOS ONE (2010)
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial
Wendy Keitel et al.
VACCINE (2010)
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic
Gavin J. D. Smith et al.
NATURE (2009)
Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus.
Kathy Hancock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
Tino F. Schwarz et al.
VACCINE (2009)
Reproducibility of Serologic Assays for Influenza Virus A (H5N1)
Iain Stephenson et al.
EMERGING INFECTIOUS DISEASES (2009)
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (HSN1) vaccine in infants and children
Terry Nolan et al.
VACCINE (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prospects for inferring very large phylogenies by using the neighbor-joining method
K Tamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
